Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post by The Wall Street Journal on X, adding:
”This WSJ article getting much attention but all studies observational.
Though signal appears to be consistent and ~42 (!) ASCO26 abstracts also reporting association b/w GLP-1 and better cancer outcomes.
Hope for RCTs to clarify true anticancer biology vs. confounding.”
Quoting The Wall Street Journal‘s post:
”The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients.”
Title: Association of GLP-1 agonists with breast cancer incidence in women.
Author: Elizabeth McDonald
Title: Weight-Loss Drugs May Have Surprising Side Effect: Stalling Cancer
Author: Xavier Martinez
Articles Featuring Nina Niu Sanfor on OncoDaily.